Abstract

Improved understanding of the molecular basis of gynecologic cancers in addition to the availability of faster and less expensive technologies for genetic analysis of cancers has led to the exciting field of targeted biologic agents in ovarian, endometrial, cervical, and vulvar cancer. These agents include antiangiogenic therapies, poly (ADP-ribose) polymerase inhibitors, phosphoinositide 3-kinase pathway inhibitors, notch inhibitors, and epidermal growth factor receptor inhibitors. This article...